We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

ERBA MANNHEIM

Erba Mannheim is an IVD solutions provider focused on improving health outcomes in developing nations. Originally fou... read more Featured Products: More products

Download Mobile App





ERBA Group Launches New Hematology Analyzers at MEDLAB 2019

By Theresa Herman, Regional Director
Posted on 27 Mar 2019
Print article
Image: ERBA Diagnostics Mannheim launched its latest hematology analyzers at MedLab Middle East (Photo courtesy of ERBA).
Image: ERBA Diagnostics Mannheim launched its latest hematology analyzers at MedLab Middle East (Photo courtesy of ERBA).
ERBA Diagnostics Mannheim GmbH (Mannheim, Germany) launched its latest hematology analyzers at MedLab Middle East, an international platform for laboratory management and medicine that was held between February 4-7, 2019, at the Dubai International Convention and Exhibition Centre, Dubai, UAE.

ERBA is a global in-vitro diagnostic company that provides a comprehensive portfolio in different specialties including clinical chemistry, immunology, hematology, hemostasis, critical care, electrophoresis, urine analysis, diabetes monitoring, autoimmune & infectious disease monitoring and microbiology. Its latest hematology analyzers, H 360 and H 560, launched at MedLab 2019 are designed for improving lab efficiency and are targeted at small to medium laboratories.

The newly launched, H 360 3-part differential analyzer can run up to 60 samples/hour and requires only 9 microliters of blood. The H 560 5-part differential analyzer also runs 60 samples/hour and requires only 15 microliters, which is highly beneficial in pediatric cases. In both systems, interpretation of results is aided using an advanced 3D scattergram. At MedLab 2019, ERBA also displayed the latest version of its fully automated urine chemistry and sediment analyzer, Laura XL which uses digital microscopy and AI technology to auto-recognize 16 urine sediment elements. Moreover, the photometric urine strip reader aids in the precise determination of 10 analytes using ERBA’s standardized test strips DekaPHAN.

ERBA’s team of experts provided a first-hand experience to the delegates on the new systems with more than 10 demonstrations being conducted each day. During the exhibition, customer interactions were complemented by a series of informational presentations conducted by industry experts and ERBA team members. Insightful discussions on the benefits of fast reporting for better treatment outcomes, validation methods for clinical chemistry systems, and the advantages of AMH ELISA testing were held, in addition to presentations on Laura XL, H 360 and 560 and the ELISA test range made by its US subsidiary, Calbiotech Inc.

“We are glad to be associated with MedLab as it offers an opportunity to interact with customers from across the world,” said Nikhil Vazirani, CEO, ERBA Group. “ERBA operates in a dynamic global economy and MedLab gives us a great opportunity to help understand changing customer needs and how we should adapt our technologies to offer seamless services. We are committed to focusing our products and solutions on the emerging markets and impacting a billion lives globally.”


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.